Quantitation Of Ivosidenib In Human Plasma Via Lc-Ms/Ms And Its Application In Clinical Trials

BIOANALYSIS(2021)

引用 6|浏览20
暂无评分
摘要
Aim: Ivosidenib is a potent and selective small molecule inhibitor of mutant isocitrate dehydrogenase 1. Accurate measurement of ivosidenib is the key to ivosidenib pharmacokinetics in clinical trials. Materials & methods: Quantitation of ivosidenib was conducted by using a stable isotope labeled compound (ivosidenib-d(4)) as the internal standard. Results: This assay was validated and successfully applied to support multiple clinical trials. Selected clinical samples were also tested by a chiral LC-MS/MS method against four ivosidenib isomer standards to exclude the possibility of in vivo racemization of ivosidenib. Conclusion: A robust LC-MS/MS method was validated for ivosidenib in human plasma. This is the first time for ivosidenib bioanalytical method in any human matrix to be reported.
更多
查看译文
关键词
acute myeloid leukemia, AML, chiral separation, human plasma, IDH inhibitor, ivosidenib, LC-MS/MS, oncology, small molecule, validation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要